Skip directly to site content Skip directly to search


Español  Other Languages


Centers for Disease Control and Prevention. CDC twenty four seven. Saving Lives, Protecting People
 Search

		Submit


Tuberculosis (TB)








Reported Tuberculosis in the United States, 2022						Print
																Related Pages
										Return to Main Menu**On This Page**
			IntroductionOverall TrendsRisk FactorsClinical CharacteristicsTB Treatment and Drug ResistanceCase OutcomeMolecular SurveillanceConclusion
Executive Commentary
Introduction
This 2022 edition of *Reported Tuberculosis in the United States* describes cases of tuberculosis disease (TB) reported to the Centers for Disease Control and Prevention (CDC) since 1993. This year’s report emphasizes cases counted by reporting areas in 2022 and the ongoing effects of the COVID-19 pandemic on TB surveillance.
Information in this report summarizes incident cases of TB reported to CDC’s National Tuberculosis Surveillance System (NTSS) by each of the 50 U.S. states and the District of Columbia (DC) unless otherwise specified. In addition to the 50 U.S. states and DC, five U.S. territories (American Samoa, Commonwealth of the Northern Mariana Islands, Guam, Puerto Rico, and the U.S. Virgin Islands) and three independent countries that are in compacts of free association with the United States (Federated States of Micronesia, Republic of the Marshall Islands, and Republic of Palau) report incident cases of TB to CDC. NTSS has collected information on all newly reported cases of TB since 1953, and cases reported since 1993 are maintained in an electronic database. Small variations in historical data included in this edition, compared with previous editions, are attributable to updated information submitted in the interim by reporting areas.
Some jurisdictions require reporting of latent TB infection (LTBI), a related condition in which TB bacteria live in the body without making a person sick. However, LTBI is not required to be reported to CDC, so this report focuses exclusively on cases of TB disease reported to NTSS.
Several tables have been removed compared with previous years to streamline the report and emphasize the most relevant and useful data. Other tables have been reconfigured to more effectively and clearly describe trends in TB epidemiology. All genotyping tables in this year’s report are based on whole-genome sequencing. Tables describing trends in recent transmission are not included because CDC’s Tuberculosis Genotyping Information Management System (TB GIMS) transitioned from conventional genotyping methods to whole genome sequence-based genotyping in July 2022. Validation of recent transmission algorithms using this new method are ongoing.
Overall Trends
In 2022, the United States reported 8,331 TB cases and an incidence rate of 2.5 cases per 100,000 persons, representing a 5.9% increase in case count and 5.5% increase in incidence rate compared with 2021. The increase in 2022 marks the second year in a row in which TB incidence increased after reaching the lowest recorded incidence rate (2.2 cases per 100,000 persons) in 2020, coinciding with the beginning of the COVID-19 pandemic. Before the COVID-19 pandemic, TB case counts and incidence rates had been steadily decreasing in the United States since 1992. TB incidence declined substantially (by 19.4%) to 2.2 cases per 100,000 persons in 2020 (Table 1), likely because of factors associated with the COVID-19 pandemic.1,2 In 2021, TB incidence partially rebounded to 2.4 cases per 100,000 persons but remained 12.5% lower compared with 2019. In 2022, TB incidence further increased to 2.5 cases per 100,000 but remained 7.7% lower compared with 2019. TB incidence appears to be gradually returning to prepandemic levels but concerns about missed or delayed diagnosis and ongoing effects of pandemic-related disruptions to public health persist. To achieve TB elimination in the United States (defined as <1 case per million persons annually),3 timely testing, expanded treatment options, and innovative prevention campaigns are necessary in the United States and globally.
The National Vital Statistics System reported 602 TB-related deaths in 2021, the most recent year for which data are available. This is relatively steady (a 0.3% increase using unrounded numbers) compared with 2020. The mortality rate for 2021 remained 0.2 deaths per 100,000 persons, a 0.2% increase from 2020 when calculated using unrounded numbers (Table 1).
Half of all U.S. TB cases in 2022 were reported by four states combined: California (22.2%), Texas (13.2%), New York, including New York City (8.6%), and Florida (6.4%). Eight states had TB incidence rates (cases per 100,000 persons) above the national incidence rate: Alaska (13.0), Hawaii (7.0), California (4.7), Texas (3.7), New York (3.6), Washington (3.2), New Jersey (3.1), and Maryland (2.5). Incidence rates among the U.S. territories and freely associated states ranged from 0.7 (Puerto Rico) to 252.1 (Republic of the Marshall Islands); however, two territorial jurisdictions were unable to send data by the reporting deadline (Table 25).

Demographics
**Origin of Birth**
Origin of birth is a prominent risk factor for TB in the United States because of the substantially greater risk of exposure to TB outside of the United States. In 2022, 6,148 (73.8%) cases of TB were reported among non-U.S.–born persons, and 2,142 (25.7%) cases were reported among U.S.-born persons; the incidence rate per 100,000 persons was 17.1 times higher among non-U.S.–born persons (13.0) than U.S.-born persons (0.8) (Table 8).
Among non-U.S.–born persons with TB in 2022, the most common countries of birth included Mexico (18.9%), the Philippines (10.9%), India (8.8%), Vietnam (8.2%), and China (6.0%) (Table 9). These countries have been the most common countries of birth among non-U.S.–born persons with TB since 2018, and they also represent substantial proportions of the non-U.S.–born population living in the United States.4 However, compared with 2021, the number of U.S. cases in 2022 increased by at least 20% among non-U.S.–born persons from Peru (+98.4%), Colombia (+57.8%), Afghanistan (+53.8%), El Salvador (+41.1%), Honduras (+37.3%), Thailand (+32.0%), Kenya (+31.6%), the Republic of the Marshall Islands (+31.4%), Guatemala (+29.8%), and Ecuador (+20.7%) (Table 9).
Among non-U.S.–born persons with TB, the percentage of cases by years since arrival in the United States decreases over time; the highest percentage of TB diagnoses occurs in the first few years since arrival in the United States. In spite of the reduced TB risk over time, approximately 1/3 of TB cases among non-U.S.–born persons occur 20 or more years after arrival in the United States.1,5 In 2022, the percentage of TB cases among non-U.S.–born persons that occurred within one year of arrival in the United States (16.9%) increased by 73.6% compared with 2021 (9.8%) and was the second highest percentage in the last decade. Also, in 2022 the percentage of cases by time since the person arrived in the United States was 13.6% for 1–4 years, 13.0% for 5–9 years, 8.2% for 10–14, 7.2% for 15–19, 8.7% for 20–24, 5.5% for 25–29, 6.6% for 30–34, 4.0% for 35–39, 9.7% for ≥40 years, and 6.5% for an unknown amount of time (Table 10).
The distribution of TB cases by origin of birth varies by state. States in which at least 90% of cases occurred among non-U.S.–born persons include Vermont (3 cases, 100%), Rhode Island (16 cases, 94.1%), Massachusetts (140, 91.5%), Idaho (10 cases, 90.9%), New Hampshire (10 cases, 90.9%). States in which less than 25% of cases occurred among non-U.S.–born persons include Wyoming (0 cases, 0%), Alaska (10 cases, 10.5%), and Mississippi (12, 22.2%) (Table 28).
**Race/Ethnicity**
The distribution of persons with TB and the TB incidence rates by race/ethnicity differs by origin of birth (Tables 3–4). Among U.S.-born persons in 2022, the highest percentage of cases occurred among non-Hispanic Black or African American persons (31.4%), followed by non-Hispanic White persons (26.3%) and Hispanic or Latino persons (25.0%). Non-Hispanic Native Hawaiian or Other Pacific Islander persons experienced the highest TB incidence rate (cases per 100,000 persons) among U.S.-born persons in 2022 (6.3), an increase compared with 5.2 in 2021. TB incidence among U.S.-born persons also increased among non-Hispanic American Indian or Alaska Native persons from 3.8 in 2021 to 4.5 in 2022 and among non-Hispanic Asian persons from 1.4 in 2021 to 1.8 in 2022. In spite of an overall decrease in TB incidence in the United States since 2019, incidence rates among non-Hispanic Native Hawaiian or Other Pacific Islander persons, non-Hispanic American Indian or Alaska Native persons, non-Hispanic Asian persons were higher in 2022 than in 2019 (Table 3).
Among non-U.S.–born persons in 2022, the highest percentage of cases occurred among non-Hispanic Asian persons (44.0%), followed by Hispanic or Latino persons (36.9%) and non-Hispanic Black or African American persons (10.4%). The highest TB incidence rate (cases per 100,000 persons) among non-U.S.–born persons occurred among persons of more than one race/ethnicity (31.2), but small overall population size estimates among persons of more than one race/ethnicity often lead to variability in incidence rates. The second highest incidence rates among non-U.S.–born persons occurred among non-Hispanic Native Hawaiian or Other Pacific Islander persons (27.8), followed by non-Hispanic Asian persons (22.7), non-Hispanic Black or African American persons (14.0), Hispanic or Latino persons (10.4), non-Hispanic White persons (3.5), and non-Hispanic American Indian or Alaska Native persons (0.0) (Table 4).
**Age**
TB incidence rates are higher among adults than among children; among persons 5 years and older, incidence rates increase with age.1 TB risk increases with age because of a combination of age-related changes in TB exposure, risk of comorbidities, and immune function.6–8 In 2022, persons 65 years and older had the highest TB incidence rate (cases per 100,000 persons) (3.9), and children aged 5–14 years had the lowest TB incidence rate (0.4). Incidence rates were steady or increased in 2022 compared with 2021 for all age groups, and the largest increase occurred among persons aged 15–24, which changed by 24.2% from 1.5 in 2021 to 1.9 in 2022. However, compared with 2019, TB incidence rates in 2022 remained the same or lower for each age group (Table 5). Among U.S.-born persons, age-specific incidence rates continued to be highest among persons 65 years and older (1.0), 0–4 years (1.0), and 45–64 years (1.0) (Table 6). Among non-U.S.–born persons, age-specific incidence rates were highest among 65 years and older (22.2), followed by persons aged 15–24 years (16.3) and 0–4 years (11.8). The incidence rate among non-U.S.–born persons aged 0–4 years increased by 265% from 3.2 in 2021 to 11.8 in 2022 (Table 7).
**Sex**
In 2022, male persons accounted for 61.9% of TB cases in the United States, including 62.5% of cases among U.S.-born persons and 61.9% of cases among non-U.S.–born persons. For U.S.-born persons and non-U.S.–persons in 2022, the percentage of cases was higher for male persons compared with female persons at every age group except ages 5–14 years. Among persons aged 5–14 years, 53.4% of cases among non-U.S.–born persons and 54.3% of cases among U.S.-born persons occurred among female persons (Table 21).
Risk Factors
**Comorbid Conditions**
Medical conditions or therapies that weaken or suppress the immune system can increase the risk for TB. Diabetes mellitus (24.3%) remains the most commonly reported medical risk factor among persons with TB and was reported by a larger percentage of non-U.S.–born persons with TB (26.9%) compared with U.S.-born persons with TB (17.1%) (Table 22). Among persons with TB in 2022 who were alive at diagnosis, human immunodeficiency virus (HIV) status was known for 89.5%, and 4.3% of persons with TB and known HIV status were coinfected with HIV (Table 17). Tumor necrosis factor-alpha (TNF-α) antagonist therapy was reported for 1.0% of cases, and 0.7% of persons had received a solid organ transplant. Other immunocompromising conditions or therapies were reported for 9.5% of cases (Table 22).
**Congregate Settings**
Living in congregate settings, including homeless shelters, correctional facilities, and long-term care facilities, is a risk factor for TB because shared airspace and poor ventilation can facilitate TB exposure and transmission. People experiencing homelessness also face challenges accessing medical care that can delay diagnosis and disrupt treatment.9 Among persons aged ≥15 years with TB in 2022, 392 (5.0%) reported experiencing homelessness within the 12 months preceding TB diagnosis (Table 32). This compares with 341 (4.5%) TB cases in 2021 among persons aged ≥15 years with reported homelessness in the past year.5
During 2022, 141 (1.8%) TB cases were diagnosed among current long-term care facility residents aged ≥15 years (Table 32) compared with 1.5% in 2021.
**Substance Use**
Substance use is also a TB risk factor; it can have physiological effects that increase risk for TB but is often a proxy for other epidemiologically important factors that increase exposure to TB.10 Substance use can also present a barrier to TB diagnosis and treatment, increasing potential infectiousness and the risk of further TB transmission.10,11 The most commonly reported type of substance use during the year preceding diagnosis among persons with TB aged ≥15 years was excess alcohol use (9.1%), followed by noninjecting drug use (7.2%), and injecting drug use (1.0%) (Table 32).
Clinical Characteristics
**Primary Reason for Tuberculosis Evaluation**
Similar to past years, experiencing TB symptoms was the primary reason for TB evaluation for the majority (60.2%) of persons with TB in the United States in 2022. Active case-finding methods, including investigation of close contacts to an infectious TB case and planned screening or “targeted testing” of groups expected to have elevated prevalence of TB infection, were reported as the primary reason for TB evaluation for 15.3% of TB cases (Table 31) compared with 13.8% of 2021 cases.1
**Site of Disease**
TB most commonly affects the lungs but can cause disease in any part of the body; 81.0% of U.S. TB cases had pulmonary involvement, a slight increase compared with 78.6% in 2021. Among the 18.8% of U.S. TB cases with only extrapulmonary TB, the most common sites affected were the lymphatic system (26.1%) and pleura (22.1%). TB meningitis, a particularly serious form of the disease, accounted for 5.8% of extrapulmonary-only cases (Table 19).
TB Treatment and Drug Resistance
Effective treatment for TB disease includes providing multiple anti-TB drugs over a sufficient period of time to cure the patient, prevent development of drug resistance, and minimize the risk of transmission to others. The most common initial treatment regimen for drug-susceptible TB and in situations where drug-susceptibility is unknown includes isoniazid, H; rifampin, R; pyrazinamide, Z; and ethambutol, E (HRZE).12 Other four-drug regimens might be appropriate for a variety of public health or clinical reasons, including drug resistance, interactions or contraindications, or supply chain problems related to one or more drugs in the HRZE regimen.13,14 Also in 2022, CDC released interim guidance for a four-drug 4-month regimen including isoniazid, rifapentine, pyrazinamide, and moxifloxacin (RPT-MOX) as a treatment option for people 12 years of age and older with drug-susceptible pulmonary TB.15
Since 2007, more than 90% of persons with TB who were alive at diagnosis had initial drug regimen information that included at least four drugs. Among persons with TB who were alive at diagnosis and had initial drug regimen information in 2022, 81.1% began treatment with HRZE and 13.0% began treatment with a four-drug regimen other than HRZE, including 17 (1.6%) persons who began treatment with RPT-MOX. Since only 6.0% received no initial drug therapy or a less than four drug regimen, the vast majority (94.0%) of TB patients alive at diagnosis reported in the United States are likely to have received appropriate initial TB therapy (Table 14).
Anti-TB drug resistance is a concern in the United States and globally. Resistance to isoniazid, one of the most common anti-TB drugs, can be a precursor to multidrug-resistant (MDR) TB, which is defined as resistance to at least isoniazid and rifampin.16 During 2022, resistance to at least isoniazid at initial diagnosis was reported for 528 (8.4%) cases, including 90 (1.4%) MDR cases in the United States (Table 11). Among U.S.-born persons, 86 (5.7%) cases were INH-resistant TB, including 11 (0.7%) cases of MDR TB (Table 12). Among non-U.S.–born persons, 439 (9.3%) cases were INH-resistant TB, including 77 (1.6%) cases of MDR TB (Table 13).
Pre-XDR TB is caused by an organism that is resistant to isoniazid, rifampin, and a fluoroquinolone or by an organism that is resistant to isoniazid, rifampin, and a second-line injectable drug (amikacin, capreomycin, and kanamycin). XDR TB is caused by an organism that is resistant to isoniazid, rifampin, a fluroquinolone, and a second-line injectable drug (amikacin, capreomycin, and kanamycin) or by an organism that is resistant to isoniazid, rifampin, a fluoroquinolone, and bedaquiline or linezolid.16 In 2022, 16 (0.3%) cases of pre-XDR TB and 5 (0.1%) cases of XDR TB were reported in the United States (Table 11).
Drug resistance is more commonly observed among persons who have previously been diagnosed with TB. Among U.S.-born persons diagnosed with TB in 2022, the percentage of persons with INH-resistant TB was 8.5% among persons who had a previous TB diagnosis compared with 5.6% among persons who had not previously been diagnosed with TB (Table 12). Among non-U.S.–born persons diagnosed with TB in 2022, the percentage of persons with INH-resistant TB was 18.0% among persons who had previously been diagnosed with TB compared with 8.6% among persons who had not previously had TB (Table 13). Stringent guidelines for TB treatment in the United States, including diligent follow-up efforts by public health personnel, greatly reduce the risk of developing drug-resistant TB.
**Directly Observed Therapy and Completion of Treatment**
Directly observed therapy (DOT) involves direct observation by a trained individual of a patient ingesting anti-TB medications to ensure patients adhere to their prescribed therapy; it can include in-person and video DOT.17 DOT is a critical case management strategy to achieve completion of TB therapy, helping prevent TB from spreading to others and avoiding development of drug-resistant TB. For cases reported in 2020, the most recent year for which data are available, TB treatment was administered using exclusively DOT for 61.5% of patients, and 31.0% received TB treatment with a combination of DOT and self-administered therapy (Table 15).
Successful completion of TB treatment is important to prevent TB recurrence and drug resistance. TB treatment completion remained relatively steady for cases reported in 2020, the most recent year for which data are available. An uncomplicated course of treatment for drug-susceptible TB takes about 4–6 months to complete; however, drug resistance or other factors can require treatment for >1 year. Among 2020 patients eligible to complete TB treatment within 1 year, 89.0% completed treatment within 1 year, compared with 90.1% in 2019, and 94.7% ever completed TB treatment, compared with 95.7% in 2019. The percentage of patients who did not complete treatment was 4.3% in 2019 compared with 5.3% in 2020 (Table 16).
Case Outcome
Among all TB cases diagnosed during 2020, 11.8% (n=845) of persons died, compared with 10.0% (n=892) in 2019. Death was attributed to TB disease or TB treatment for 325 (38.5%) persons which is the largest number in a single year since 2011 (347 deaths). Of the 845 deaths, 208 (24.6%) occurred in persons who were dead at the time of diagnosis; TB was reported as a cause of death for 28.8%. The remaining 637 (75.4%) deaths occurred after diagnosis, of which 265 (41.6%) were related to TB disease or therapy (Table 18).
Molecular Surveillance
TB genotyping is a laboratory-based approach used to analyze genetic material (e.g., DNA) of *Mycobacterium tuberculosis*; characterizing distinct genetic patterns facilitates distinguishing certain *M. tuberculosis* strains from others. This is the first year CDC is reporting genotyping results using wgMLSType (whole-genome multilocus sequence type), a typing method based on whole-genome sequencing. In previous years conventional genotyping methods (spoligotyping and mycobacterial interspersed repetitive unit-variable number tandem repeats [MIRU-VNTR]) were used to report genotyping results. Whole-genome sequencing methods examine nearly the entire *M. tuberculosis* genome compared with conventional methods that examine a small portion. CDC transitioned to using wgMLSType exclusively for genotyping in July 2022, although wgMLSType is available for all *M. tuberculosis* isolates since January 2018. Genotype surveillance coverage, defined as the percentage of culture-positive TB cases with a genotyped isolate, was 96.0% in 2022 (Table 33).
A TB case is considered clustered if the wgMLSType of the case’s isolate matched one or more cases’ isolates in the same county or county-equivalent area during the 3-year period 2020–2022. Clustered TB cases might indicate recent TB transmission. CDC generates cluster alerts (i.e., medium alert and high alert) based on the degree of geospatial concentration of cases with matching wgMLSType within the same county or county-equivalent area compared with the concentration of the wgMLSType outside of the given county or county-equivalent. CDC reviews medium and high alerts weekly for possible programmatic follow-up.
The percentage of clustered genotyped cases during 2019–2021 (19.2%) based on conventional genotyping methods in last year’s report1 compares with 16.9% clustering during 2020–2022 based on whole-genome sequencing methods (Table 23). Clustering percentages were 37.1% among U.S.-born persons during 2020–2022 compared with 34.6% reported in 2019–2021, and 10.0% among non-U.S.–born persons in 2020–2022 compared with 13.5% in 2019–2021.1 The number of clusters reported nationally also declined in 2020–2022 (987) compared with 2019–2021 (1,241),1 a 20.5% reduction when using whole-genome sequencing from last year’s report using conventional genotyping (Table 24).
Among clustered cases, the percentage that were in medium or high alert clusters during 2020–2022 was 65.7% compared with 38.3% reported using conventional genotyping in 2019–2021.1 Percentages of clustered cases in alerted clusters varied across population subgroups during 2020–2022. By origin of birth, percentages of clustered cases in alerted clusters were higher among U.S.-born persons (72.8%) compared with non-U.S.–born persons (56.9%). By race/ethnicity, percentages were highest among American Indian or Alaska Native persons (96.1%) and lowest among Hispanic or Latino persons (54.2%). By age group, percentages were highest among persons aged 0–4 (79.2%) and lowest among persons aged 65 or older (60.5%). Among risk factors for TB disease, persons residing in correctional facilities at the time of TB diagnosis had the highest percentage in alerted clusters (75%) (Table 23).
Conclusion
In 2022, reported TB cases and incidence rates in the United States increased for the second year in a row but remained lower than levels reported prior to the COVID-19 pandemic. The pandemic caused substantial changes in immigration and travel, health care and public health services, social exposures, and mortality, which likely led to a combination of TB underdiagnosis and a true reduction in TB incidence in the United States throughout 2020–2021. In 2022, the pandemic waned, but the effects of the pandemic on the public health workforce and public health resources persisted.18–20
Compared with prepandemic 2019 levels, TB incidence rates remained the same or lower for both U.S.-born and non-U.S.–born persons and all age groups except U.S.-born persons aged 5–14 years and non-U.S.–born persons aged 0–4 years. TB among young children is particularly concerning because is usually results from recent transmission instead of reactivation of long-standing LTBI. TB incidence remained steady or below prepandemic levels for most U.S.-born race and ethnicity groups, but increased among American Indian or Alaska Native persons, Native Hawaiian or Other Pacific Islander persons, and Asian persons, increasing the TB disparities experienced by those populations.
Birth outside of the United States remains a key risk factor for TB, with a TB incidence rate 17.1 times higher in non-U.S.–born persons compared with U.S.-born persons in 2022. The number of TB cases diagnosed among non-U.S.–born persons within the first year after arrival in the United States nearly doubled compared with 2021 and reached the highest level since 2016. Even though the most common countries of birth among people diagnosed with TB in the United States has remained steady for many years, small but noteworthy increases occurred among persons born in several Central and South American countries as well as Afghanistan. Changes in the number of TB cases diagnosed among non-U.S.–born persons by years since arrival and country of birth might reflect changes in migration patterns, including increased arrivals among persons evacuating from conflict zones.21–23
In addition to birth origin, social and medical factors can increase the risk of being infected with TB and progression to TB disease. Diabetes mellitus affects approximately 10% of the U.S. population24 but was reported in 2022 for about one-quarter of persons with TB. Diabetes can increase the risk of developing TB disease among persons with TB infection,25 as can other immunocompromising conditions such as HIV and renal failure. Even though the prevalences of some social risk factors, such as residing in a congregate setting and substance use, have declined among persons with TB over the last decade,1 these factors continue to affect a substantial number of persons with TB in the United States.
Because of the two-year reporting lag for TB case outcomes data, this report is the first to include treatment outcome data for TB cases diagnosed during the first year of the COVID-19 pandemic. The number of deaths attributed to TB disease or TB treatment in 2020 was the highest since 2011, especially among persons who died after diagnosis. This is consistent with a higher TB-related death rate reported in 2020 vital statistics data.1 However, decreases in treatment completion and directly observed therapy for cases diagnosed in 2020 were minimal, suggesting that in spite of the staffing and resource challenges that health departments faced in 2020, TB programs were able to ensure treatment completion rates similar to the levels observed in the years before the COVID-19 pandemic.
TB epidemiology appears to be returning to prepandemic levels in many respects, and invigorated efforts are necessary to achieve TB elimination in the United States. Testing for TB is critical for populations at higher risk for TB infection and progression, including people with weak immune systems due to HIV, renal failure, or other conditions such as diabetes. Increased efforts to detect and treat LTBI are also needed to accelerate progress towards TB elimination. Innovations such as shorter regimens15 and video-directly observed therapy17 should be considered, in combination with other proven TB prevention activities, to test and treat persons at risk for TB.ReferencesCenters for Disease Control and Prevention. Reported tuberculosis in the United States, 2021. Accessed August 14, 2023. https://www.cdc.gov/tb/statistics/reports/2021/default.htm
Winglee K, Hill AN, Langer AJ, Self JL. Decrease in tuberculosis cases during COVID-19 pandemic as reflected by outpatient pharmacy data, United States, 2020. *Emerg Infect Dis.* 2022;28(4):820-827. doi:10.3201/eid2804.212014
Centers for Disease Control and Prevention. Division of Tuberculosis Elimination strategic plan 2016-2020. Accessed July 30, 2020. https://www.cdc.gov/tb/about/strategicplan.htm
U.S. Census Bureau. Public Use Microdata Sample (PUMS) documentation. Accessed November 14, 2019. https://www.census.gov/programs-surveys/acs/microdata/documentation.2019.html
Talwar A, Li R, Langer AJ. Association between birth region and time to tuberculosis diagnosis among non-US-born persons in the United States. *Emerg Infect Dis.* 2021;27(6):1645-1653. doi:10.3201/eid2706.203663
Kim S, Cohen T, Horsburgh CR, et al. Trends, mechanisms, and racial/ethnic differences of tuberculosis incidence in the US-born population aged 50 years or older in the United States. *Clin Infect Dis Off Publ Infect Dis Soc Am.* 2022;74(9):1594-1603. doi:10.1093/cid/ciab668
Iqbal SA, Winston CA, Bardenheier BH, Armstrong LR, Navin TR. Age-period-cohort analyses of tuberculosis incidence rates by nativity, United States, 1996-2016. *Am J Public Health*. 2018;108(S4):S315-S320. doi:10.2105/AJPH.2018.304687
Byng-Maddick R, Noursadeghi M. Does tuberculosis threaten our ageing populations? *BMC Infect Dis.* 2016;16:119. doi:10.1186/s12879-016-1451-0
Centers for Disease Control and Prevention. TB and people experiencing homelessness. Published August 16, 2023. Accessed September 6, 2023. https://www.cdc.gov/tb/topic/populations/homelessness/default.htm
Deiss RG, Rodwell TC, Garfein RS. Tuberculosis and drug use: review and update. *Clin Infect Dis Off Publ Infect Dis Soc Am.* 2009;48(1):10.1086/594126. doi:10.1086/594126
Oeltmann JE, Kammerer JS, Pevzner ES, Moonan PK. Tuberculosis and substance abuse in the United States, 1997-2006. *Arch Intern Med.* 2009;169(2):189-197. doi:10.1001/archinternmed.2008.535
Nahid P, Dorman SE, Alipanah N, et al. Official American Thoracic Society/Centers for Disease Control and Prevention/Infectious Diseases Society of America clinical practice guidelines: treatment of drug-susceptible tuberculosis. *Clin Infect Dis Off Publ Infect Dis Soc Am.* 2016;63(7):e147-e195. doi:10.1093/cid/ciw376
Chorba T. Dear colleague letter: TB drug supply interruptions and shortages. Published May 11, 2023. Accessed August 18, 2023. https://www.cdc.gov/tb/publications/letters/2023/tb-drug-shortage.html
Higashi J. Los Angeles County Department of Public Health Health Advisory: temporary national shortage of rifampin oral capsules. Published March 2, 2022. Accessed August 18, 2023. http://publichealth.lacounty.gov/eprp/lahan/alerts/LAHAN_RifampinPOCapsuleShortage03022022%20v2.pdf
Carr W, Kurbatova E, Starks A, Goswami N, Allen L, Winston C. Interim guidance: 4-month rifapentine-moxifloxacin regimen for the treatment of drug-susceptible pulmonary tuberculosis – United States, 2022. *MMWR Morb Mortal Wkly Rep.* 2022;71(8):285-289. doi:10.15585/mmwr.mm7108a1
Langer AJ, Starks AM. Dear colleague letter: surveillance definitions for extensively drug resistant (XDR) and pre-XDR tuberculosis. Published January 18, 2022. Accessed August 31, 2022. https://www.cdc.gov/tb/publications/letters/2022/surv-def-xdr.html
Mangan JM, Woodruff RS, Winston CA, et al. Recommendations for use of video directly observed therapy during tuberculosis treatment – United States, 2023. *MMWR Morb Mortal Wkly Rep.* 2023;72(12):313-316. doi:10.15585/mmwr.mm7212a4
Kirkland C, Oldfield-Tabbert K, Karnik H, Orr J, Martin S, Leider JP. Public health workforce gaps, impacts, and improvement strategies from COVID-19. *Int J Environ Res Public Health.* 2022;19(20):13084. doi:10.3390/ijerph192013084
Hare Bork R, Robins M, Schaffer K, Leider JP, Castrucci BC. Workplace perceptions and experiences related to COVID-19 response efforts among public health workers – Public Health Workforce Interests and Needs Survey, United States, September 2021-January 2022. *MMWR Morb Mortal Wkly Rep.* 2022;71(29):920-924. doi:10.15585/mmwr.mm7129a3
Trust for America’s Health. The impact of chronic underfunding on America’s public health system: trends, risks, and recommendations, 2022. Accessed August 14, 2023. https://www.tfah.org/report-details/funding-report-2022/
U.S. Department of Homeland Security. Operation Allies Welcome. Accessed August 25, 2022. https://www.dhs.gov/allieswelcome
Congressional Research Service. Central American migration: root causes and U.S. policy. Accessed September 20, 2023. https://crsreports.congress.gov/product/pdf/IF/IF11151
Ward N, Batalova J. Central American immigrants in the United States. migrationpolicy.org. Published May 9, 2023. Accessed September 20, 2023. https://www.migrationpolicy.org/article/central-american-immigrants-united-states
Centers for Disease Control and Prevention. The facts, stats, and impacts of diabetes. Published April 4, 2023. Accessed September 6, 2023. https://www.cdc.gov/diabetes/library/spotlights/diabetes-facts-stats.html
Centers for Disease Control and Prevention. TB and diabetes. Published November 17, 2022. Accessed September 6, 2023. https://www.cdc.gov/tb/topic/basics/tb-and-diabetes.html
							
					
							Last Reviewed:  November 15, 2023						Source: 	Division of Tuberculosis Elimination, National Center for HIV, Viral Hepatitis, STD, and TB Prevention, Centers for Disease Control and Prevention
					Facebook
        Twitter
        LinkedIn
        Syndicate homeTuberculosisBasic TB Factsplus iconHow TB SpreadsLatent TB Infection and TB DiseaseSigns & SymptomsTB Risk FactorsExposure to TBTB PreventionVaccinesTB & HIV CoinfectionTB and DiabetesTB TermsPersonal StoriesTesting & Diagnosisplus iconWho Should be TestedTesting for TB InfectionTesting in BCG-Vaccinated PersonsTB Screening and Testing of Health Care PersonnelTesting During PregnancyDiagnosing latent TB infection and TB diseaseTreatmentplus iconDeciding When to Treat Latent TB InfectionTreatment Regimens for Latent TB Infection (LTBI)Treatment for TB DiseaseAdverse EventsTB Treatment of Persons Living with HIVTB Treatment and PregnancyTB Treatment for ChildrenFrequently Asked QuestionsDrug-Resistant TBResearchplus iconTB Epidemiologic Studies Consortiumplus iconResearch ProjectsPublicationsTB Trials Consortiumplus iconStudy DescriptionsBackgroundBehavioral & Social Science ResearchHealth Care Settingsplus iconTB Infection Control in Health Care SettingsResources for TB Screening and Testing of Health Care Personnelplus iconFrequently Asked QuestionsTB in Specific Populationsplus iconHealth DisparitiesAsian PersonsBlack or African American PersonsHispanic or Latino PersonsChildrenPregnancyCorrectional FacilitiesPeople Experiencing HomelessnessInternational TravelersLaboratory Informationplus iconDrug Susceptibility TestingFalse-Positive Investigation ToolkitInterim Laboratory Biosafety Guidance for XDR  tuberculosis strainsModel Performance Evaluation Program (MPEP)Rapid Molecular Testing to Detect Drug-Resistant TB in the USplus iconExecutive SummaryIntroductionBackground on Tests for Molecular Detection of DRGeneral Considerations and Principles for a Molecular DR Testing ServicePossible Scenarios and Scope of Testing for a Molecular DR Testing ServiceResearch NeedsGeneral Recommendations of the Expert PanelCommunication Plan for the ReportRecommendationsReferencesPanel Members and CDC ParticipantsAppendix 1Appendix 2Appendix 3The Uses of Nucleic Acid Amplification Tests for the Diagnosis of TBplus iconGeneral ConsiderationsGeneral Recommendations of the Expert PanelRecommendations to ACET, CDC, DTBEData & Statisticsplus iconTB Incidence in the United StatesReported TB in the US, 2022 Surveillance Reportplus iconNational DataReporting Area DataRisk FactorsDemographicsTB Treatment and Case OutcomesDrug-Resistant TBMolecular SurveillanceTuberculosis in the United States, 2022 (Slide Set)Archived Surveillance Reports and Slide Sets2021 State and City ReportArchived State and City ReportsProfessional Resources & Toolsplus iconTools for Healthcare ProvidersResources for TB Programsplus iconStrengthening Civil Surgeons’ Capacity to Improve LTBI Surveillance and Outcomes Among Status AdjustersNotice of Funding Opportunity (NOFO)Program EvaluationTB Centers of ExcellenceTB Elimination AllianceTB Genotypingplus iconConventional TB GenotypingWhole Genome SequencingTB GIMSAnalytic ToolsLatent Tuberculosis Infection ResourcesPublications & Productsplus iconPatient and Public MaterialsFact SheetsGuidelinesplus iconControl & EliminationDrug-Resistant TBInfection Control & PreventionLaboratory & GenotypingTB & HIVTB in Specific PopulationsTesting & DiagnosisTreatmentVaccines & ImmunizationsArchived TB GuidelinesGuides & Toolkitsplus iconAggregate ReportsCDC TB Surveillance TrainingCore CurriculumEffective TB Interviewing for Contact InvestigationEthnographic GuidesFalse-Positive Investigation ToolkitForging Partnerships to Eliminate TuberculosisGuide to Application of GenotypingLTBI: A Guide for Primary Health Care ProvidersMantoux Tuberculin Skin Testing ProductsReport of Verified Case of Tuberculosis (RVCT)Self-Study ModulesTB Contact Investigation Interviewing Skills CourseTB eDOT ToolkitUnderstanding the TB Cohort Review ProcessNewslettersplus iconTB Notes, No. 4, 2023TB Notes, No. 3, 2023TB Notes. No. 2, 2023TB Notes. No. 1, 2023TB Notes, No. 4, 2022TB Notes, No. 3, 2022TB Notes, No. 2, 2022TB Notes, No. 1, 2022TB Notes, No. 4, 2021TB Notes, No. 3, 2021TB Notes, No. 2, 2021TB Notes, No. 1, 2021Pamphlets, Brochures, Bookletsplus iconQuestions and AnswersPatient Education SeriesTuberculosis - Get the FactsTuberculosis - The Connection between TB and HIV12-Dose Regimen for Latent TB Infection-Patient Education BrochurePostersplus iconMantoux Tuberculin Skin Test Wall ChartWorld TB DayThink TBStop TBTake on TBReports & Articlesplus iconDTBE Authored Journal ArticlesTuberculosis Laboratory Aggregate ReportsSlide Setsplus iconIntroduction to TuberculosisEpidemiology of Tuberculosis Among Non-U.S.​–Born Persons in the United States, 1993–2016Self-Study Modules on Tuberculosis, 1-5 Slide SetsThe Tuberculosis (TB) in Correctional Settingsplus iconFacilitator GuideIntroduction to TB GenotypingEpidemiology of Tuberculosis in Correctional Facilities, United States, 1993-2017Prevention and Control of Tuberculosis in Correctional and Detention FacilitiesGuidelines for Preventing the Transmission of M. TB in Health care SettingsInvestigation of Contacts of Persons with Infectious TBEpidemiology of Pediatric Tuberculosis in the United StatesTargeted Tuberculosis Testing and Treatment of Latent Tuberculosis InfectionElectronic Tools & ResourcesWeb-Based Courses & Webinarsplus iconTB 101 for Health Care WorkersContent SyndicationInfographicsplus iconSocial Media GraphicsCustomizable Take on TB Infographic with InstructionsEventsWorld TB Dayplus iconU.S. TB ChampionsHistoryFeaturesplus iconTB Risk FactorsTreating Latent TB Infection with Short-Course RegimensWorld Tuberculosis (TB) Day 2021World Tuberculosis (TB) Day 2020Linksplus iconState TB Control OfficesAbout Usplus iconMission Statement and Activitiesplus iconDTBE Strategic PlanNational TB Program ObjectivesOrganization ChartAdvisory Groupsplus iconFederal TB Task Force To receive email updates about this page, enter your email address: Email Address			What's this?				Submit


About CDC
					Contact Us
					800-232-4636
 Facebook Twitter Instagram LinkedIn Youtube Pinterest Snapchat
 CONTACT CDC
				Contact Us
							Call 800-232-4636
							Email Us
			ABOUT CDC
				About CDC
							Jobs
							Funding
			POLICIES
				Accessibility
							External Links
							Privacy
							Policies
							No Fear Act
							FOIA
							OIG
							Nondiscrimination
							Vulnerability Disclosure Policy
			CONNECT WITH US
				Facebook
								Twitter
								Instagram
								LinkedIn
							Youtube
								Pinterest
								Snapchat
								Email
			LANGUAGES
				Español
							繁體中文
							Tiếng Việt
							한국어
							Tagalog
							Русский
							العربية
							Kreyòl Ayisyen
							Français
							Polski
							Português
							Italiano
							Deutsch
							日本語
							فارسی
							English


U.S. Department of Health & Human Services
			Accessibility
			External Links
			Privacy
			Policies
			No Fear Act
			FOIA
			Nondiscrimination
			OIG
			Vulnerability Disclosure Policy
			USA.gov


Exit Notification / Disclaimer Policy Close
 Links with this icon  indicate that you are leaving the CDC website. The Centers for Disease Control and Prevention (CDC) cannot attest to the accuracy of a non-federal website.
				Linking to a non-federal website does not constitute an endorsement by CDC or any of its employees of the sponsors or the information and products presented on the website.
				You will be subject to the destination website's privacy policy when you follow the link.
				CDC is not responsible for Section 508 compliance (accessibility) on other federal or private website. Website Disclaimers
 Cancel Continue